Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.
In the first of these mini-reviews the selection of therapy for the maintenance of sexual function in patients with BPH is outlined, along with an explanation of how altered regulation of neurotransmitters, especially noradrenaline, may underlie the syndrome of LUTS and sexual dysfunction. Other mini-reviews outline the current status of robotic surgery to treat renal and adrenal disorders, and its future applications, and the potential use of the nitric oxide/cGMP pathway as a potential target to treat BOO associated with benign prostatic enlargement. Finally, the capacity to be creative in academic departments is extolled as a core property of academicians, and its surfacing described as having the potential to revitalize individuals and departments.
Nehra
Ajay
A
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. nehra.ajay@mayo.edu
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000517:prevention & control; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010410:Penile Erection / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control*
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D001378:Azasteroids; D004791:Enzyme Inhibitors; D018120:Finasteride; D000068538:Dutasteride